Nick Zanotta

[Nick Zanotta @Naz31289]

A great read for those working in pharmacy operations. A breakdown of what the ICH E6 (R3) update means for investigational product management and how it impacts workflows and compliance. Check it out: https://t.co/xeGiBb9Lcr

[Nick Zanotta @Naz31289]

See you at OCT West Coast. Joinus at booth #43 for conversations on rare oncology research. Juliane Mills, Exec. Director, TSL, Rare Disease, will be speaking on how rare oncology differs from other rare diseases, and what that means for your team’s... https://t.co/ftadM9tEgI

[Nick Zanotta @Naz31289]

Worldwide Welcomes Peter Robinson https://t.co/ULfLYHfgmM

[Nick Zanotta @Naz31289]

Curious about where GLP-1 therapies are headed? This webinar series featuring Judith Hey-Hadavi, VP of Medical Affairs, breaks down key topics shaping emerging therapies and how Worldwide is connecting analytical science with clinical trials. Worth... https://t.co/BRs2lU7vwG

[Nick Zanotta @Naz31289]

This white paper gives an in-depth look at how basket trials are being used in immunology research to speed up signal detection and streamline development, including the scientific, operational, and regulatory challenges your teams can plan for. https://t.co/ppkDDg3zkS

[Nick Zanotta @Naz31289]

Headed to SCOPE in Orlando? Make sure to stop by booth #621 to meet members of our team, including Scott Palmese, Executive Director, Site-Focused Solutions. He'll be on the "Collaboration & Partnership Models for Success" session, February 4 at 8:30 am... https://t.co/RTSsZwafNF

[Nick Zanotta @Naz31289]

Jorge Araneta, Senior Director, Technical Delivery & Analytics, shares his perspective on why data quality at Worldwide is more about systems and technology. It's about the people and processes behind it. See where we’re ranked: https://t.co/yPWjBey3CJ

[Nick Zanotta @Naz31289]

Headed to WORLDSymposium 2026 in San Diego? Make sure to stop by booth #608 and meet members of our rare disease team. We would love to connect and share insights on study design and patient outreach! You can schedule a meeting here: https://t.co/wMsnm52X4K

[Nick Zanotta @Naz31289]

In respiratory research, understanding the patient journey is paramount. This year, we specifically engaged with patients living with IPF and caregivers. The findings from this survey are available in this article, and I highly recommend taking a look. https://t.co/8YPa1ETB42

[Nick Zanotta @Naz31289]

So proud of the team at Worldwide Clinical Trials! We stepped in to transition two Disease Monitoring Programs for a biotech that was facing delayed payments and communication breakdowns. Our team got both programs running efficiently. Read our case... https://t.co/cSN7zyEtjo

[Nick Zanotta @Naz31289]

This article explores the latest advancements in rapid-acting antidepressants and what it means for patients, including faster relief, reduced risk, and more support during their most vulnerable moments. https://t.co/AZfFjz3sDP

[Nick Zanotta @Naz31289]

Kate Smith, Executive Director of Early Phase Trials, highlights why Australia and New Zealand offer unique advantages for early-phase research, from fast regulatory approvals, R&D savings, diverse recruitment and integration into global plans. https://t.co/u5Vw1epa95

[Nick Zanotta @Naz31289]

New insights into the future of Parkinson’s disease research are here. Alicia Bian’s poster from AAPS 2025 offers a great look into how Worldwide is measuring a challenging biomarker with greater precision. If you’re interested in how these findings... https://t.co/1MVNblN3xb

[Nick Zanotta @Naz31289]

THIS is an end-of-year recap worth sharing. In 2025, we added over 25 new clinical research sites to our network, which helped our teams streamline operations, expand patient access, and deliver even more high-quality studies around the world. https://t.co/Uni5sQLIva

[Nick Zanotta @Naz31289]

What a wrap for our global oncology and rare disease teams. 2025 brought major milestones, from record-breaking trial numbers and meaningful progress across multiple therapies. Proud to be a part of such tangible impact! Check out the year in review. https://t.co/R6LQpx37Mg

[Nick Zanotta @Naz31289]

And that’s a wrap on an incredible and impactful year. In 2025, Worldwide served patients across 68 countries, powered by the care, collaboration, and commitment of our teams. Proud to be part of this global effort! https://t.co/N6Enx93DFE

[Nick Zanotta @Naz31289]

I’m so proud to be on a team dedicated to making significant strides in Alzheimer’s and dementia research! Find out how our Worldwide team can help support your neuroscience drug development program by scheduling a meeting with them at AD/PD: https://t.co/auSta8xIYw

[Nick Zanotta @Naz31289]

Understanding multiple sclerosis means understanding patients – their challenges, their patient journey, and their goals for the future. This Multiple Sclerosis Awareness Week, I’m proud to be at a CRO that prioritizes the patient in our clinical trials! https://t.co/GSvuOuWmrJ

[Nick Zanotta @Naz31289]

Did you know that our team at Worldwide includes neuropsychologists and neuroimaging experts who have worked on the development of every drug class applicable to dementia diseases in the past 30 years? Find out what else sets our team apart today: https://t.co/5Rt9dCiRRo

[Nick Zanotta @Naz31289]

Given the recent surge in GLP-1 agonists, it’s critical to understand management strategies between comorbid conditions as well as the rebound effect associated with GLP-1 agonist discontinuation. Check out our infographic to learn more: https://t.co/kT0W45udwR